- Home
- NEUE vs ABOS Comparison
NEUE vs ABOS Comparison
Compare NEUE & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUE
- ABOS
- Stock Information
- Founded
- NEUE 2015
- ABOS 1996
- Country
- NEUE United States
- ABOS United States
- Employees
- NEUE N/A
- ABOS N/A
- Industry
- NEUE
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- NEUE
- ABOS Health Care
- Exchange
- NEUE NYSE
- ABOS Nasdaq
- Market Cap
- NEUE 61.3M
- ABOS 60.6M
- IPO Year
- NEUE 2021
- ABOS 2021
- Fundamental
- Price
- NEUE $6.81
- ABOS $1.20
- Analyst Decision
- NEUE Hold
- ABOS Strong Buy
- Analyst Count
- NEUE 1
- ABOS 4
- Target Price
- NEUE $7.00
- ABOS $6.50
- AVG Volume (30 Days)
- NEUE 5.3K
- ABOS 304.2K
- Earning Date
- NEUE 08-06-2025
- ABOS 08-12-2025
- Dividend Yield
- NEUE N/A
- ABOS N/A
- EPS Growth
- NEUE N/A
- ABOS N/A
- EPS
- NEUE N/A
- ABOS N/A
- Revenue
- NEUE $907,349,000.00
- ABOS N/A
- Revenue This Year
- NEUE $33.99
- ABOS N/A
- Revenue Next Year
- NEUE $5.90
- ABOS N/A
- P/E Ratio
- NEUE N/A
- ABOS N/A
- Revenue Growth
- NEUE N/A
- ABOS N/A
- 52 Week Low
- NEUE $3.79
- ABOS $0.86
- 52 Week High
- NEUE $7.66
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- NEUE 50.30
- ABOS 53.50
- Support Level
- NEUE $6.77
- ABOS $1.05
- Resistance Level
- NEUE $6.83
- ABOS $1.31
- Average True Range (ATR)
- NEUE 0.05
- ABOS 0.09
- MACD
- NEUE -0.00
- ABOS 0.01
- Stochastic Oscillator
- NEUE 37.50
- ABOS 48.61
About NEUE NEUEHEALTH INC
NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.